Most common Entyvio side effects, like fatigue, headache, and nausea, resolve within a few days after each infusion. Because Entyvio (vedolizumab) works selectively in the gut rather than throughout the entire body, its side effect profile tends to be milder and shorter-lived than many other biologic therapies for inflammatory bowel disease. That said, the timeline varies depending on whether you’re dealing with a routine reaction to an infusion or a rarer, more serious complication.
Common Side Effects After Each Infusion
The side effects most people notice after an Entyvio infusion are similar to what you might feel after a flu shot: fatigue, headache, nausea, joint pain, and cold-like symptoms such as a stuffy or runny nose. These typically appear within the first 24 to 48 hours after treatment and fade on their own within one to three days. Some people barely notice them at all, while others feel wiped out for a day or two before bouncing back.
Joint pain can be a bit more persistent. Some patients report achiness that lingers for several days after an infusion, occasionally up to a week. If joint pain becomes a recurring pattern that worsens over multiple infusions rather than improving, that’s worth bringing up with your treatment team, as it may signal something other than a temporary infusion response.
Infusion Reactions and Allergic Responses
Infusion-related reactions can happen during the infusion itself or up to several hours afterward. These range from mild flushing, rash, or itchiness to more serious symptoms like difficulty breathing, a rapid heartbeat, or a spike in blood pressure. Mild reactions often resolve within minutes to a few hours once the infusion is slowed or stopped. More significant reactions, like hives or bronchospasm, may require treatment but still typically clear within hours.
Anaphylaxis is rare but possible with any infusion, including the very first one. These reactions develop quickly and are treated immediately, with symptoms resolving in the hours that follow. Infusion reactions can occur with any dose, not just early ones, so the possibility doesn’t disappear after you’ve had several uneventful treatments.
Why Entyvio’s Side Effects Differ From Other Biologics
Entyvio was designed to be gut-selective. It targets a specific protein on immune cells that directs them to the intestine, blocking those cells from flooding into gut tissue and driving inflammation. Older biologics like infliximab and adalimumab work by neutralizing an inflammatory signal called TNF-alpha throughout the entire body, which is effective but also suppresses immune function more broadly. That systemic suppression is why those drugs carry higher risks for widespread infections and other complications.
An earlier drug called natalizumab targeted a related protein but wasn’t specific enough. It also blocked immune cell movement to the brain, which created a risk for a rare and often fatal brain infection. Entyvio was specifically engineered to avoid that problem. It does not interfere with immune cell trafficking to the brain, and over eight years of safety monitoring, no cases of that brain infection have been reported in Entyvio patients.
This gut-focused design means that side effects tend to stay localized and shorter in duration. You’re less likely to experience the kind of prolonged immune suppression that leads to lingering infections or slow-healing illnesses.
Infection Risk During Treatment
Because Entyvio dials down immune activity in the gut, upper respiratory infections, sinus infections, and gastrointestinal bugs are among the more commonly reported issues during treatment. These infections aren’t caused by the drug directly but reflect a slightly reduced immune response in certain tissues. They follow normal illness timelines: a cold lasts a week or so, a sinus infection may take a couple of weeks.
Long-term safety data tracking patients over eight years found no increasing trend in infection rates over time. The risk doesn’t appear to compound the longer you stay on the medication, which is reassuring for people on maintenance therapy. The overall safety profile remained stable with no unexpected concerns emerging in extended follow-up.
Liver Problems: Rare but Slower to Resolve
Liver injury is a rare but documented complication. In reported cases, symptoms of acute hepatitis appeared as early as two weeks after the first infusion. Signs include yellowing of the skin or eyes, dark urine, unusual fatigue, and pain in the upper right abdomen. Once the medication was stopped, liver enzyme levels normalized over the following weeks, though “weeks” is notably longer than the day-or-two recovery from common side effects.
This is one of the few Entyvio side effects where the resolution timeline stretches beyond a few days. If you develop any signs of liver trouble, your doctor will likely check blood work and may discontinue treatment. The good news is that liver function does recover once the drug is out of your system.
How Long Entyvio Stays in Your System
Entyvio has a half-life of roughly 25 days, meaning it takes about that long for half the drug to clear from your body. For the medication to be essentially gone, you’re looking at around four to five months after your last dose. This matters because if you’re experiencing a side effect tied to the drug’s ongoing presence, it won’t vanish overnight after stopping treatment. Effects that are directly linked to the medication’s activity will gradually fade as levels drop over those weeks and months.
For most people on maintenance dosing (every four or eight weeks), side effects that pop up after each infusion follow a predictable rhythm. They peak in the first couple of days, ease off, and don’t carry over into the weeks before your next dose. If a symptom persists continuously between infusions rather than cycling with each dose, that’s more likely related to your underlying condition than to the drug itself.
What Changes Over Time on Entyvio
Some patients find that infusion-day side effects become milder after the first few treatments as their body adjusts. The induction phase, which involves three infusions over the first six weeks, can feel rougher than the maintenance phase simply because the doses are closer together. Once you shift to infusions every four or eight weeks, your body has more recovery time between treatments.
Over eight years of tracked data involving patients with both ulcerative colitis and Crohn’s disease, the most frequently reported issues were flares of the underlying disease itself, occurring in about 35 to 36 percent of patients. No new categories of side effects emerged with prolonged use, and rates of serious complications like malignancies and severe infections did not trend upward over time. For a biologic therapy, that long-term stability is notable.